tripeptide tyroservatide

01/01/2016 - "Tyroservatide (YSV) can inhibit the growth and metastasis of mouse lung cancer significantly. "
01/01/2017 - "To develop an alternative treatment for lung cancer, a combination of two potent chemotherapeutic agents - liposomal apigenin and tyroservatide - was developed. "
01/01/2017 - "Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer."
01/01/2016 - "Therapeutic effects of tyroservatide on metastasis of lung cancer and its mechanism affecting integrin-focal adhesion kinase signal transduction."
04/01/2007 - "This study aimed to observe the effects of tyroservatide on other five human carcinomas: A549 (nonsmall cell lung carcinoma), BGC-823 (gastric cancer), MCF-7 (breast cancer), K562 (leukemia), A375 (melanoma) and two murine cancers: Lewis lung cancer and B16 (melanoma) in vivo. "

04/01/2007 - "The results obtained indicate that tyroservatide exhibits different effects on different tumors, which will provide clinical applications guidance of tyroservatide as an anticancer drug."
04/01/2007 - "Inhibition of five xenografted human cancers and two murine cancers by the tripeptide tyroservatide."
06/01/2006 - "Tyroservatide may significantly inhibit the growth of human hepatocarcinoma in nude mice by inducing apoptosis and inhibiting proliferation of tumor cells."
03/01/2006 - "Gene-chip analysis of the effect of tripeptide tyroservatide (YSV) on gene-expression in human hepatocarcinoma BEL-7402 tumors transplanted to nude mice."
01/01/2006 - "The tripeptide tyroservatide (tyrosyl-seryl-valine, p-Tyr-Ser-Val-NH(2), YSV) has been shown to have anti-tumor effects on experimental hepatocarcinoma. "

01/15/2011 - "Tyroservatide (YSV) is an active, low-molecular weight polypeptide shown to have antitumor effects on experimental hepatocarcinoma and lung carcinoma. "
01/15/2011 - "Effects of tyroservatide on histone acetylation in lung carcinoma cells."
04/01/2007 - "Tyroservatide could significantly inhibit the growth of human lung carcinoma A549, human leukemia K562 and human melanoma A375 in nude mice (P<0.05). "
11/01/2012 - "Tyroservatide (YSV) is an active, low-molecular-weight peptide shown to have antimetastasic effects on experimental melanoma and lung carcinoma. "
11/01/2012 - "Tyroservatide therapy for tumor invasion and metastasis of human ovarian carcinoma and colon carcinoma."

04/01/2007 - "In addition, tyroservatide significantly inhibited the subcutaneous tumor growth of Lewis lung carcinoma and B16 melanoma (P<0.05). "
11/01/2012 - "Tyroservatide (YSV) is an active, low-molecular-weight peptide shown to have antimetastasic effects on experimental melanoma and lung carcinoma. "
04/01/2007 - "This study aimed to observe the effects of tyroservatide on other five human carcinomas: A549 (nonsmall cell lung carcinoma), BGC-823 (gastric cancer), MCF-7 (breast cancer), K562 (leukemia), A375 (melanoma) and two murine cancers: Lewis lung cancer and B16 (melanoma) in vivo. "

04/01/2007 - "This study aimed to observe the effects of tyroservatide on other five human carcinomas: A549 (nonsmall cell lung carcinoma), BGC-823 (gastric cancer), MCF-7 (breast cancer), K562 (leukemia), A375 (melanoma) and two murine cancers: Lewis lung cancer and B16 (melanoma) in vivo. "
01/01/2017 - "Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment."